bought and will hold now.
Yahoo Insider Transactions
Nov 28, 2012 ENGLER ROBERTDirector 15,000 Direct Purchase at $5.57 per share. 83,550
Nov 13, 2012 SHAFFER JAMES POfficer 20,000 Direct Purchase at $5.22 per share. 104,399
Nov 12, 2012 FALBERG KATHRYN EDirector 50,000 Direct Purchase at $5.21 per share. 260,500
Aug 26, 2012 KELLEY KENNETH JDirector 20,000 Direct Purchase at $5.70 per share. 114,000
Aug 12, 2012 FROST GREGORY IANOfficer 2,000 Direct Purchase at $5.50 per share. 11,000
Jun 4, 2012 KIRK RANDAL JDirector 5,463 Indirect Purchase at $7.48 per share. 40,863
Jun 3, 2012 KIRK RANDAL JDirector 89,646 Indirect Purchase at $7.37 per share. 660,691
May 31, 2012 KIRK RANDAL JDirector 99,080 Indirect Purchase at $7.39 per share. 732,201
May 16, 2012 KIRK RANDAL JDirector 299,007 Indirect Purchase at $7.50 per share. 2,242,552May 15, 2012KIRK RANDAL JDirector 344,910 Indirect Purchase at $7.44 per share. 2,566,130
May 14, 2012 KIRK RANDAL JDirector 427,581 Indirect Purchase at $7.35 per share. 3,142,720
Seeking Alpha Market Currents June 26, 2013
Baird analyst Brian Skorney weighs in on the Sarepta (SRPT +1.4%) debate today, saying that...
Wednesday, June 26
Baird analyst Brian Skorney weighs in on the Sarepta (SRPT +1.4%) debate today, saying that management is firm on its guidance for a breakthrough designation on Eteplirsen.
to verify go to Google put in jen mcnary twitter.
Alex Ruetz @ruetzal18 25 Jun
@jennmcnary what's the next step for the FDA? We waiting on a late July meeting?
6:42 AM - 25 Jun 13 · Detailsjenn mcnary jenn mcnary @jennmcnary 25 Jun
@ruetzal18 I believe thats what $srpt CEO said- late july, I will be in contact with FDA between now and then.
ACAD Has No real Catalyst Until 2014, so people are putting money into HALO and XOMA etc.. that have catalyst in less than a week... just a guess but I'm still holding ACAD anyway. cheap here.
Halozyme's Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
Nearly two-thirds of patients in trial with high levels of hyaluronan responded to treatment
PR NewswirePress Release: Halozyme Therapeutics, Inc. – Mon, Jun 3, 2013 7:52 AM EDT